Adma Biologics (ADMA) Net Equity Issued and Repurchased (2012 - 2022)

Adma Biologics' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $64.6 million for Q4 2022.

• Quarterly Net Equity Issued and Repurchased rose 20.09% year-over-year to $64.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $64.6 million (down 46.64% YoY) and the FY2022 annual result came in at $64.6 million, down 46.64% from the prior year.
• Net Equity Issued and Repurchased was $64.6 million for Q4 2022 at Adma Biologics, up from $53.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $88.7 million in Q1 2020 and bottomed at -$1280.0 in Q3 2018.
• A 5-year average of $36.5 million and a median of $36.9 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 68.99% in 2021, while the deepest fall reached 52.75% in 2021.
• Adma Biologics' Net Equity Issued and Repurchased stood at -$1280.0 in 2018, then soared by 3781122.5% to $48.4 million in 2019, then slumped by 34.19% to $31.9 million in 2020, then jumped by 68.99% to $53.8 million in 2021, then increased by 20.09% to $64.6 million in 2022.
• Business Quant data shows ADMA's Net Equity Issued and Repurchased at $64.6 million in Q4 2022, $53.8 million in Q4 2021, and $8.2 million in Q3 2021.